Rate Video

ECC 2015 | Exploratory analysis of frontline therapies in REVEL: Phase 3 trial of ramucirumab in NSCLC

Giorgio Scagliotti • 26 Sep 2015

Lung Cancer Docetaxel Ramucirumab

At the European Cancer Congress (ECC) 2015, Giorgio Scagliotti, MD, PhD, from the University of Turin, Turin, Italy, discusses the exploratory analysis of frontline therapies in REVEL, a randomized phase 3 trial of ramucirumab plus docetaxel versus docetaxel for the treatment of patients with stage IV non-small cell lung cancer (NSCLC) after disease progression on platinum-based therapy.

ASCEND-1 and ASCEND-2: Ceritinib for ALK-rearranged NSCLC and baseline brain metastases

Giorgio Scagliotti • 15 Apr 2016

More evidence needed to support checkpoint inhibitor use in late-stage cancer

Giorgio Scagliotti

Phase 2 trial of chemotherapy plus gefitinib as first-line treatment for lung adenocarcinoma

Giorgio Scagliotti • 15 Apr 2016

Future steps in translational medicine for early to late stage lung cancer

Giorgio Scagliotti

Related Videos

CROWN: biomarkers for lorlatinib response in patients with ALK+ NSCLC

Alessandra Bearz • 12 Apr 2021

NADIM: baseline ctDNA as a prognostic factor for PFS

Mariano Provencio • 9 Apr 2021

Mobocertinib for previously treated NSCLC with EFGR mutations

Alex Spira • 7 Apr 2021

CANOPY-A: canakinumab for resected NSCLC

Alex Spira • 7 Apr 2021